The microtubule-associated protein tau is an intrinsically disordered protein containing a few short and transient secondary structures. Tau physiologically associates with microtubules (MTs) for its stabilization and detaches from MTs to regulate its dynamics. Under pathological conditions, tau is abnormally modified, detaches from MTs, and forms protein aggregates in neuronal and glial cells. Tau protein aggregates can be found in a number of devastating neurodegenerative diseases known as “tauopathies”, such as Alzheimer’s disease (AD), frontotemporal dementia (FTD), corticobasal degeneration (CBD), etc. However, it is still unclear how the tau protein is compacted into ordered protein aggregates, and the toxicity of the aggregates is still debated. Fortunately, there has been considerable progress in the study of tau in recent years, particularly in the understanding of the intercellular transmission of pathological tau species, the structure of tau aggregates, and the conformational change events in the tau polymerization process. In this review, we summarize the concepts of tau protein aggregation and discuss the views on tau protein transmission and toxicity.
Hit-to-lead optimization is a multi-objective molecular-design problem in which binding-related scores must be considered together with drug-likeness and synthetic accessibility. We developed a closed-loop language-model medicinal-chemistry agent that combines target and starting-hit context, PubMed retrieval, molecular-property tools, docking, and feedback from previously scored analogues. In a matched computational benchmark comprising six kinase targets, six methods, a 40-candidate budget, and six independent campaigns per method, the agent achieved the highest mean aggregate score under a pre-specified composite objective on four targets. Re-analysis of the same candidate sets with drug-likeness-gated docking and docking-drug-likeness hypervolume produced different target-level winners, showing that evaluation rules can change the comparative interpretation of an optimization campaign. Candidate distributions and component ablations indicated that the agent’s advantage was associated primarily with retention of scored-candidate feedback and higher-QED regions rather than with docking alone. An EGFR case study illustrates a scaffold-preserving in-silico optimization trajectory from erlotinib. The study is a computational benchmark and evaluation framework; the prioritized molecules are hypotheses for subsequent experimental testing, not experimentally validated leads.
Hit-to-lead optimization must balance binding-related performance with drug-likeness, synthetic accessibility, and early safety considerations. We developed an iterative large language model agent that integrates target and starting-hit context, literature and computational tools, multi-property scoring, and feedback from previously scored analogs. A matched benchmark covered six kinase targets, five comparison strategies, a 40-candidate budget, and six independent campaigns per method. The agent achieved the highest mean aggregate score on four targets under an objective combining docking, quantitative estimate of drug-likeness (QED), synthetic accessibility, and a rule-based property panel. Re-evaluating the same candidate sets using drug-likeness-gated docking and docking-drug-likeness hypervolume produced different target-level winners, showing that metric choice changes the comparative interpretation of optimization campaigns. Candidate distributions showed higher-QED regions alongside improved docking, and ablation identified scored-candidate feedback as the most consistent contributor. In an epidermal growth factor receptor campaign, an erlotinib analog retained the 4-anilinoquinazoline core while improving docking from -6.80 to approximately -8.6 kcal mol⁻¹ and QED from 0.418 to approximately 0.73. These computational results support target-specific agent evaluation and candidate prioritization for subsequent biochemical, cellular, and ADMET characterization.
Identifying which gene drives a desired cell-state transition is a foundational inverse problem in target discovery and cell-state engineering, yet far less developed than forward prediction. We show that prevailing benchmarks inflate performance through two artefacts: training leakage, where test-perturbation cells are seen during fitting, and evaluation leakage, where the perturbed gene’s own expression change exposes the answer. Here, we introduce Cause-excluded Effect Evaluation (CEE), a framework that separates train and test perturbation targets, removes target-gene self-effects from expression profiles and scores candidates in downstream response space. With CEE, we find that simple structure-based methods consistently outperform complex deep learning models across 16 single-cell perturbation datasets, revealing that the recoverable signal is governed by low-rank and additive structure in perturbation responses rather than by model complexity. Our work disentangles evaluation artefacts from genuine predictive capacity and offers a design principle for developing perturbation target identification methods.